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Ethnopharmacological relevance: The infusion or decoction of Mirabilis jalapa leaves is used in traditional
medicine in Brazil to treat inﬂammatory and painful diseases. Thus, the present study was designed to
investigate whether the leaf ethyl acetate (Eta) fraction from Mirabilis jalapa exhibits antinociceptive
effect in clinically relevant pain models in mice. Furthermore, we have investigated the role of
cholinergic system in the antinociceptive action produced by Eta in mice.
Materials and methods: The effect of Eta administered orally (10 mg/kg, p.o.) in mice was veriﬁed on the
painful hypersensitivity (mechanical allodynia) in models of chronic inﬂammation (subcutaneous
injection of complete Freund’s Adjuvant—CFA in the plantar surface of the right hind paw), postoperative
(paw surgical incision) and neuropathic (partial sciatic nerve ligation) pain. In the chronic inﬂammation
model, we further veriﬁed the effect of Eta treatment on paw edema and interleukin-1β (IL-1β) levels. We
also investigated the role of muscarinic and nicotinic receptors in the antiallodynic action produced by
Eta as well as the possible action of Eta on in vitro and ex vivo acetylcholinesterase activity in CFA treated
animals. Furthermore, we veriﬁed the effect of Eta treatment on the parameters of liver and kidney lesion
(level of urea, and activity of aspartate aminotransferase and alanine aminotransferase).
Results: Eta produced marked reduction in the allodynia caused by CFA, surgical incision and partial
sciatic nerve ligation. However, Eta did not alter the paw edema or the increase of IL-1β levels produced
by CFA. The antinociceptive effect of Eta was reversed by the pre-treatment of animals with the
antagonists of muscarinic (atropine, 5 mg/kg, s.c) or nicotinic (mecamylamine, 0.001 mg/kg, s.c.)
receptors. Eta did not alter in vitro acetylcholinesterase activity in blood or spinal cord samples, but it
reversed the increase in the acetylcholinesterase activity observed in the spinal cord samples from mice
injected with CFA. Moreover, Eta did not alter the indicators of liver or kidney lesion.
Conclusions: Based on its use in traditional medicine, the results of the present study conﬁrmed the
antinociceptive properties of Eta in clinically relevant pain models. Also its effect on the CFA-induced
chronic inﬂammation seems to be related to acetylcholinesterase inhibition and cholinergic system.
& 2013 Elsevier Ireland Ltd. All rights reserved.d Ltd. All rights reserved.
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alker).1. Introduction
The therapeutic treatments available today to treat painful
diseases usually have limited effectiveness and safety, particularly
to treat chronic pain. In fact, the repeated use of the non-steroid
anti-inﬂammatory drugs by arthritic patients may induce several
adverse effects, such as gastrointestinal lesions or renal and liver
failure (Rao and Knaus, 2008; Lam and Ng, 2010). Furthermore,
some painful conditions, such as neuropathic pain, are refractory
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Hagen, 1990; Ferreira et al., 2005; Trevisan et al., 2009). It is
therefore very important to search for new products that may be
used in the treatment of such illnesses. Over the years, natural
products have shown to be an unparalleled source of molecular
diversity leading to drug discovery currently used in modern
medicine, especially in the treatment of pain (Shu, 1998; Silva
et al., 2012).
Mirabilis jalapa belongs to the family Nyctaginaceae and is
popularly known as ‘maravilha’ or ‘bonina’ in Brazil and ‘four
o’clock’ in different countries. Its leaves are used as decoction or
infusion in folk medicine in Southern Brazil to treat inﬂammatory
and painful diseases (Corrêa, 1984; Siddiqui et al., 1990; Somavilla
and Canto-Dorow, 1996; Lorenzi and Souza, 1999). Recently, we
have reported that Mirabilis jalapa ethyl acetate fraction (Eta)
presented antinociceptive effect in acetic acid-induced writhing
and tail-ﬂick tests in mice, an effect that was dependent of
muscarinic, but not opioid receptors (Walker et al., 2008). We also
observed that single oral treatment with Eta did not alter loco-
motor activity, body temperature or gastrointestinal transit and
did not produce gastric lesions (Walker et al., 2008). Thus, Eta
presents an attractive pharmacological proﬁle (efﬁcacious anti-
nociceptive properties and reduced side effects), which suggests
its use in pathological painful conditions. However, the antinoci-
ceptive effect of Mirabilis jalapa was until now only veriﬁed in
acute and non-clinically relevant models of pain.
Therefore, the present study was designed to investigate
whether Eta exhibits antinociceptive effects in three models of
pain, arthritic pain caused by paw injection of complete Freund’s
Adjuvant (CFA), postoperative pain caused by surgical incision and
neuropathic pain induced by partial sciatic nerve ligation in mice.
Furthermore, we have investigated the role of cholinergic system
in the antinociceptive action produced by Eta.2. Materials and methods
2.1. Plant material
The leaves of Mirabilis Jalapa were collected in March 2006, in
Santa Maria, in the State of Rio Grande do Sul, Brazil. A voucher
specimen number SMDB 10.077 was deposited at the Herbarium
of the Botany Department, Federal University of Santa Maria
(UFSM), Brazil.
2.2. Extraction and fractionation
Fresh leaves were dried under ventilation (45 1C). Then pow-
dered dried leaves were macerated with ethanol/water (70:30) at
room temperature. The crude hydroethanolic extracts was con-
centrated until dryness in a rotary evaporator. The dry hydro-
ethanolic extract was dissolved in methanol/water (10:90) and
partitioned with n-hexane, dichloromethane, ethyl acetate or
n-butanol, respectively. All the fractions were tested in a previous
study and the ethyl acetate fraction was more efﬁcacious and
potent to induce antinociception. Moreover, the ethyl acetate
fraction did not present toxicity (Walker et al., 2008). For this
reason, the ethyl acetate fraction was chosen in the current study
to be tested in different pain models and termed Eta.
2.3. Drugs and reagents
The following reagents were purchased from Sigma: CFA (sus-
pension of heat-killed Mycobacterium tuberculosis in oil, 1 mg/mL),
tween 20, tween 80, phenylmethanesulfonylﬂuoride (PMSF), dia-
minoethanetetraacetic acid (EDTA), antitrypsin, bacitracin, bovineserum albumin (BSA), atropine, mecamylamine, triton X-100, 5,5′-
dithiobis-2-nitrobenzoic acid (DTNB), ethopropazine and
acetylthiocholine (ATC).
Enzyme-linked immunoassay for IL-1β measurement was pur-
chased from R&D Systems and the colorimetric kit for alanine
aminotransferase (ALT), aspartate aminotransferase (AST), urea
and creatinine was purchased from LabTest.
2.4. Animals
Adult male albino Swiss mice (25–35 g) bred in our animal
house were used. Animals were housed at controlled temperature
(2272 1C) with a 12 h light/dark cycle, standard lab chow and tap
water ad libitum. Animals were habituated to the experimental
room for at least 2 h before the experiments and used only once.
All protocols employed have been approved by the Local Ethic’s
Committee (process number: 23081.010134/2007-66) and are in
accordance with the US guidelines for the care and use of
Laboratory animals (NIH publication #85-23, revised in 1985).
The number of animals and intensity of noxious stimuli used were
the minimum necessary to demonstrate the consistent effects of
the drug treatments (Zimmermann, 1983).
2.5. Drug administration
A previous study carried out in our laboratory showed that the
dose of 10 mg/kg of Eta was more efﬁcacious and potent to induce
antinociception (Walker et al., 2008). Thus, we have used this dose
to investigate the antinociceptive effect of this plant in several
pain models. A solution of saline (NaCl 0.9%) plus 20% polyethile-
noglycol and 5% tween 80 was used as vehicle to administrate Eta.
2.6. Nociception measurement
The nociception was measured by the intensity of mechanical
allodynia, considered as a painful hypersensitivity produced by the
previously innocuous mechanical stimuli, which is a relevant
characteristic of pathological chronic pain (Loeser and Treede,
2008). Mechanical allodynia was assessed using the up–down
paradigm as described previously (Souza et al., 2008). Mice were
placed in clear plastic chambers (7911 cm) on an elevated
surface and allowed to acclimatize to their environment for 2 h
before testing. Von Frey ﬁlaments of increasing stiffness (0.02–
10 g) were applied to the mice hind paw plantar surface with a
pressure causing the ﬁlament to bend. Absence of a paw lifting
after 5 s led to the use of the next ﬁlament with increasing weight,
and paw lifting indicated a positive response and led to the use of
next weaker ﬁlament. This paradigm continued until a total of six
measurements. The 50% mechanical paw withdraw threshold
response was then calculated from the resulting scores as
described previously (Dixon, 1980). The frequency of mechanical
paw withdrawal was determined before (baseline), after nocicep-
tion induction, and also after Eta administration in different time
points.
2.7. Chronic inﬂammation model: CFA-induced nociception, edema
and IL-1β increment
The investigation of the antinociceptive and anti-inﬂammatory
property of Eta was ﬁrst evaluated in the CFA-induced paw
inﬂammation, a model of chronic arthritic pain. Before CFA
injection, baseline measurement of mechanical paw withdrawal
(described above) and paw thickness (assessed with a calipter—
Mytutoio, Japan) was carried out as described before (Milano et al.,
2008). After baseline measurements, animals were anesthetized
with halothane and 20 mL of CFA was injected subcutaneously into
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et al., 2001), control animals were injected with saline (0.9% NaCl,
20 mL). Forty eight hours after, the development of mechanical
allodynia (reduction in the paw withdrawal threshold) and paw
edema (increase in the paw thickness as compared with baseline
values) was assessed as previously described (Milano et al., 2008).
To evaluate the acute effect of Eta, animals received a single
administration of Eta (10 mg/kg, p.o.) or vehicle orally. The
mechanical allodynia and the paw edema were measured from
30 min to 24 h after treatment. To investigate the effects of the
repeated treatment, mice received one injection of Eta (10 mg/kg,
p.o.) or vehicle daily for 7 days. On days 1 to 7, mechanical
allodynia and the paw edema were evaluated before and 1 h after
treatment (day 1 corresponds to the ﬁrst day of the treatment,
48 h after CFA or saline injection). The measurements taken before
the daily injection of the drugs were used to verify the cumulative
effect of the treatment and those taken 1 h after treatments were
used to identify the development of tolerance.
2.8. IL-1β levels quantiﬁcation
Two hours after the end of the last chronic administration of
Eta, the animals were euthanized by pentobarbital overdose
(10 mg/kg, i.p.) and the tissue of paw was immediately collected
and stored in liquid nitrogen. On the day of analysis, the tissue was
defrosted and placed in an 80 mM PBS (pH 7.4) solution contain-
ing: 0.5% Tween 20, 0.1 mM PMSF, 2 mM EDTA, 0.01 mg/mL
antitrypsin, 0.1% bacitracin and 0.1% BSA. The tissue was homo-
genized, centrifuged at 16,000 g for 10 min at 4 1C and the
supernatant obtained was used to determine the IL-1β levels with
an enzyme-linked immunoassay. Using a curve plotted from
standard solutions, cytokine level was calculated as pg IL-1β/mg
tissue.
2.9. Postoperative pain model: surgical incision-induced nociception
The postoperative pain model was carried out according to the
procedure described on mice (Pogatzki and Raja, 2003; Milano
et al., 2008). Before surgery, baseline measurement of mechanical
paw withdrawal was carried out. Later, mice were anesthetized
with 2% halothane via a nose cone. After anti-septic preparation of
the right hind paw, a 5-mm longitudinal incision was made with a
number 11 blade through the skin and fascia of the plantar foot.
The incision was started 2 mm from the proximal edge of the heel
and extended toward the toes. The underlying muscle was
elevated with a curved forceps, leaving the muscle origin and
insertion intact. The skin was apposed with a single mattress
suture of 6.0 nylon. Control mice underwent a sham procedure
that consisted of anesthesia and antiseptic preparation without an
incision.
Mechanical allodynia was measured as described above. The
preventive effects of the orally administered drugs were evaluated
in the mice receiving either Eta (10 mg/kg, p.o.) or vehicle (10 mg/
mL, p.o.), 0.5 h before the incisional procedure. To evaluate
the curative effect of the drugs, the animals received Eta (10 mg/
kg, p.o.) or vehicle (10 mg/mL, p.o.), 1 h after the incisional
procedure. Either in preventive or curative treatment, mechanical
allodynia was recorded 1, 2, 4, and 6 h after administration.
2.10. Neuropathy model: partial sciatic nerve ligation-induced
nociception
Neuropathic pain was induced by a partial ligation of the sciatic
nerve under deep anesthesia (Ferreira et al., 2005; Souza et al.,
2008; Trevisan et al., 2009). Brieﬂy, mice were anesthetized
intraperitoneally using a mixture of 90 mg/kg of ketamine plus3 mg/kg of xylazine. A partial ligation of the right sciatic nerve was
made by tying one-third to one half of the dorsal portion of the
sciatic nerve (Malmberg and Basbaum, 1998). In sham-operated
mice, the nerve was exposed without ligation. Seven days after
surgical procedure, the mechanical allodynia was evaluated at
different intervals (0.5, 1, 2 and 4 h) after Eta (10 mg/kg, p.o) or
vehicle (10 mg/mL, p.o) treatment. Before neuronal trauma, base-
line measurement of mechanical paw withdrawal was carried out,
and also after 7 days after the procedure.
2.11. Assessment of cholinergic system involvement in the
antinociceptive activity of Eta
We have previously described the participation of muscarinic
system over the antinociception induced by Eta (Walker et al.,
2008); here we have investigated the participation of cholinergic
system on the antinociceptive effect of Eta in the CFA-induced
nociception, as described above. Baseline measurement of
mechanical paw withdrawal was carried out and then mice were
injected with CFA. Forty-eight hours later, mechanical allodynia
was measured and mice were pre-treated with atropine (5 mg/kg,
subcutaneous route, s.c.; a muscarinic receptor antagonist), meca-
mylamine (0.001 mg/kg, s.c.; a nicotinic receptor antagonist), or
vehicle. Fifty minutes after, mice were treated with Eta (10 mg/kg,
p.o) or vehicle and 75 min after, mechanical allodynia was mea-
sured again. The choice of the dose of agonists and antagonists and
their treatment times was based on the previous data described in
the literature (Sheardown et al., 1997; Yue et al., 2007).
The ex vivo activity of acetylcholinesterase was assessed after
the 1 hour after single treatment of Eta (10 mg/kg, p.o.) or vehicle
(10 mg/mL, p.o.) administration in mice pretreated (48 h prior)
intraplantarly with CFA or saline. The animals were euthanized by
pentobarbital overdose (10 mg/kg, i.p.) and tissues (whole blood
and spinal cord sample) were collected to detect the enzyme
activity. Blood was immediately collected from the hepatic vein,
using a heparinized syringe, and diluted 1:100 in phosphate buffer
(0.1 M, pH 7.4) with 0.03% Triton X-100. Lumbar portion of the
spinal cord was also collected by mechanical extrusion using cold
saline. Spinal cord samples were homogenized in 1 mL of potas-
sium phosphate buffer (0.1 mM, pH 7.4) and diluted 1:5 in the
same buffer. After preparation, both samples were frozen (20 1C)
until analysis of the acetylcholinesterase activity.
The reaction was started adding 500 mL of blood sample, 1 mL
of phosphate buffer and 50 mL of DTNB 10 mM. After pre-
incubation in a water bath at 37 1C during 3 min, the reaction
was initiated by adding acetylthiocholine (ATC, 28.4 mM). To
evaluate the effect of Eta on lumbar spinal cord or brain, 25 mL of
sample, 1 mL of potassium phosphate buffer and 50 mL of DTNB
(23 mM) were mixed. After pre-incubation in a water bath at 30 1C
for 2 min, the reaction was initiated by adding ATC (36 mM). The
development of color was measured at 436 nm for blood (Worek
et al., 1999) and 412 nm for spinal cord (Pereira et al., 2004).
Results were expressed in mM ATC hydrolyzed/hour/mg protein.
For the in vitro acetylcholinesterase activity, blood of naïve
mice was collected from the hepatic vein, using a heparinized
syringe. The sample was diluted 1:100 in phosphate buffer (0.1 M,
pH 7.4) with 0.03% Triton X-100. Lumbar spinal cord samples were
also collected from the same animals by mechanical extrusion
using cold saline. These samples were homogenized in 1 mL of
potassium phosphate buffer (0.1 mM, pH 7.4) and diluted 1:5 in
the same buffer. After preparation, both samples were frozen until
analysis.
The reaction was started adding 25 mL of Eta (1 and 10 mg/mL)
to 500 mL of blood sample, 1 mL of phosphate buffer, 50 mL of DTNB
10 mM and 10 mL of ethopropazine (3 mM). After pre-incubation in
a water bath at 37 1C for 5 min, the reaction was initiated by
Fig. 1. Effect of single Eta (10 mg/kg, p.o.) administration on mechanical allodynia
(A) or edema formation (B) induced by CFA paw injection in mice. The mechanical
allodynia or edema formation were observed 48 h after the injection of CFA
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acetylcholinesterase, 25 mL of Eta (1 and 10 mg/mL) was added to
25 mL of spinal cord sample, 1 mL of potassium phosphate buffer
and 50 mL of DTNB 23 mM. After pre-incubation in a water bath at
30 1C for 5 min, the reaction was initiated by adding ATC (36 mM).
The color development was measured at 436 nm for blood (Worek
et al., 1999) and 412 nm for spinal cord (Pereira et al., 2004).
Results were expressed in Δextinction/minute.
2.12. Toxicological analysis
To verify if Eta (10 mg/kg, p.o.) repeated treatment for 7 days
induces any biochemical or physiological alteration, 2 h after the
last administration the animals were sacriﬁced using pentobarbi-
tal overdose (10 mg/kg, i.p.). After that blood samples were
obtained from hepatic vein, and also stomach, heart, kidney,
spleen and liver. The activity of ALT and AST were measured as
indicators of hepatic injury, while the urea level was used an
indicator of renal lesion. In addition, the organs and body weight
were measured and compared. The percentage of weight of the
organs in relationship to body weight was calculated.
2.13. Statistical analysis
Results were expressed as mean7S.E.M. The percentages of
inhibition are reported as the mean7S.E.M. of inhibition obtained
in each individual experiment in relation to the control values
(vehicle). The signiﬁcance level was set at po0.05. Data were
analyzed using Student’s t-test, one-way analysis of variance
(ANOVA) followed by Student–Newman–Keuls (SNK) post-hoc test
or two-way ANOVA followed by Bonferroni post-hoc test.(time 0). The antinociceptive and antioedematogenic effects were evaluated at
different time points (0.5, 1, 2, 4, and 24 h) after treatment with the Eta (10 mg/kg,
p.o.) or vehicle (10 mL/kg, p.o.). Basal values (B) were observed before CFA injection.
Data are expressed as the mean7S.E.M. of the mechanical painful hypersensitivity,
expressed as 50% mechanical paw withdrawal threshold (PWT) in g, or variation in
paw thickness of 6 mice. *po0.05, **po0.01, ***po0.001, compared with time
0 values, or #po0.001, compared with basal values (two-way ANOVA followed by
Bonferroni post-hoc test).3. Results
3.1. Effects of Eta on mechanical allodynia and paw edema induced
by intraplantar injection of CFA
It was possible to observe that the intraplantar injection of CFA
produced marked mechanical allodynia (paw withdrawal thresh-
old diminished from 2.1570.33 g at baseline to 0.2470.04 g 48 h
after CFA administration; po0.001, Student’s t-test) and paw
edema (paw thickness increased from 3.8070.11 mm at baseline
to 5.0370.06 mm 48 h after CFA administration; po0.001, Stu-
dent’s t-test) 48 h after injection. The single oral administration of
Eta (10 mg/kg, p.o.) reduced mechanical allodynia induced by CFA
from 0.5 to 4 h after administration (Fig. 1A), with an inhibition of
72715% observed 1 h after Eta administration. However, the
single treatment with Eta (10 mg/kg, p.o.) failed to reduce the
paw edema produced by intraplantar injection of CFA in the same
time points where antiallodynic effect was observed (Fig. 1B). Also
the single oral administration of Eta (10 mg/kg, p.o.) or vehicle
(10 mL/kg, p.o.) did not alter the paw withdrawal threshold or paw
thickness in animals previously injected with saline (data not
show, p40.05, two-way ANOVA followed by Bonferroni).
To investigate the effects of the repeated treatment of Eta, mice
received one injection of Eta (10 mg/kg, p.o.) or vehicle (10 mL/kg, p.o.)
daily for 7 days. From days 1 to 7, mechanical allodynia and the paw
edema were evaluated before and 1 h after each Eta administration. In
Fig. 2A and B, the threshold responses and paw edema of the animals
1 h after treatment from days 1 to 7 are shown. The results obtained
demonstrated no decrease in the effectiveness of the Eta antiallodynic
effect during the observation period (Fig. 2A). However, different from
single treatment, repeated treatment with Eta was capable of reducing
paw edema on days 4–7 (Fig. 2B). The Fig. 2C and D showed the
cumulative effect (24 h after each administration) of repeatedtreatment with Eta (10 mg/kg, p.o.) or vehicle (10 mL/kg, p.o.) daily
on CFA-induced allodynia and edema, respectively. The values from
days 1 to 6 represent the thresholds 24 h after drug administration
onwards. It is possible to note, in Fig. 2C, that Eta showed antinoci-
ceptive action from day 3 up to the last day of observation. Eta
treatment also reduced paw edema from day 4 to day 6 (Fig. 2D). In
addition, the repeated oral administration of Eta (10 mg/kg, p.o.) or
vehicle (10 mL/kg, p.o.) did not change the paw withdrawal threshold
or paw thickness in animals previously injected with saline (data not
show, p40.05, two-way ANOVA followed by Bonferroni).
3.2. Effects of Eta on the IL-1β levels in the CFA model
Wewere not capable of detecting IL-1β in paw tissue of animals
7 days after intraplantar saline injection. However, intraplantar
CFA injection caused a detectable increase in IL-1β level in
inﬂamed tissue 7 days after CFA injection (Fig. 3). The repeated
treatment with Eta for 7 days was not able to signiﬁcantly alter the
increase of the IL-1β levels in CFA-injected mice (Fig. 3).
3.3. Effects of Eta on mechanical allodynia induced by paw surgical
incision
Once we observed Eta effect over CFA chronic inﬂammation
model, we next investigated its preemptive and curative effect
over acute nociception induced by paw incision. The plantar
Fig. 2. Effect of repeated Eta (10 mg/kg, p.o.) administration (1 h after in A and B, or 24 h after in C and D) on mechanical allodynia (A and C) or edema formation (B and D)
induced by CFA paw injection in mice. The mechanical allodynia or edema formation were observed from 48 h (time 0) to 7 days after the injection of CFA.
The antinociceptive and antioedematogenic effects were evaluated at different time points (from 1 to 7 days) after treatment with the Eta (10 mg/kg, p.o.) or vehicle
(10 mL/kg, p.o.) Basal values (B) were observed before CFA injection. Data are expressed as the mean7S.E.M. of mechanical painful hypersensitivity, expressed as 50%
mechanical paw withdrawal threshold (PWT) in g, or variation in paw thickness of 6 mice. *po0.05, **po0.01, ***po0.001, compared with time 0 values, or #po0.001,
compared with basal values (two-way ANOVA followed by Bonferroni post-hoc test).
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Fig. 3. Effect of the repeated treatment with Eta (10 mg/kg, p.o.) and vehicle
(10 mg/mL, p.o.) for 7 days on interleukin-1β (IL-1β) levels in skin paw samples of
animals treated with CFA. Results are expressed as pg of IL-1β per mg of tissue.
Results represent the mean7S.E.M. of 6 animals. **po0.01 denotes the signiﬁ-
cance level when compared with saline paw injected animals plus vehicle-treated
mice (one-way ANOVA followed by Bonferroni post hoc test).
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paw (paw withdrawal threshold diminished from 2.1770.45 g at
baseline to 0.0470.02 g 1 h after plantar incision; po0.001,
Student’s t-test). Preventive treatment with Eta (10 mg/kg, p.o.,
0.5 h before paw incision) signiﬁcantly decreased mechanical
allodynia from 1 to 2 h after treatment with an inhibition of
3376%, observed 2 h after treatment (Fig. 4A). The curative
treatment with Eta (10 mg/kg, p.o., 1 h after incision) also reducedmechanical allodynia only 2 h after treatment, with an inhibition
of 571% (Fig. 4B).
3.4. Effects of Eta on the mechanical allodynia induced by partial
nerve ligation
We next investigated the Eta effect in an animal model of
neuropathic pain. The partial ligation of mice sciatic nerve pro-
duced a decrease of mechanical threshold (paw withdrawal
threshold diminished from 2.3070.38 g at baseline to 0.047
0.02 g 7 days after partial nerve ligation; po0.001, Student’s
t-test), measured 7 days after nerve injury, compared to the
sham-operated group (Fig. 5A). Eta (10 mg/kg, p.o.) was markedly
effective in reducing the mechanical allodynia from 0.5 to 2 h after
treatment (Fig. 5A), with an inhibition of 71716%. Moreover, Eta
did not alter the detection of normal mechanical stimuli assessed
in sham-operated mice (Fig. 5B).
3.5. Effect of cholinergic system on Eta antinociceptive effect
We next investigated the participation of muscarinic and
nicotinic receptors in Eta antiallodynic effect on the chronic
inﬂammatory pain model induced by CFA. The treatment of mice
either with the muscarinic receptor antagonist atropine (5 mg/kg,
s.c.) or with the nicotinic receptor antagonist mecamylamine
(0.001 mg/kg, s.c.) prevented the antiallodynic effect of Eta
(10 mg/kg, p.o.) in the CFA model (Fig. 6A and B).
As an alteration on AChE activity may lead to an increase in the
acetylcholine levels, resulting in antinociception through cholinergic
Fig. 4. Time-course for the preventive (A) or curative (B) effect of Eta (10 mg/
kg, p.o.) on mechanical allodynia caused by paw incision. The mechanical allodynia
was observed 1, 2, 4 or 6 h after Eta (10 mg/kg, p.o.) or vehicle (10 mg/mL, p.o.)
administration in mice. For the preventive effect Eta or vehicle were administered
0.5 h prior the incisional procedure, for curative effect Eta or vehicle were injected
1 h after the incisional procedure. Basal values (B) were observed before the
incisional procedure. Data are expressed as the mean7S.E.M. of mechanical painful
hypersensitivity, expressed as 50% mechanical paw withdrawal threshold (PWT) in
g of 6 animals. *po0.05 and **po0.01, compared with time 0 values (after the
procedure) or vehicle-treated group, or #po0.001, compared with basal values
(two-way ANOVA followed by Bonferroni post-hoc test).
Fig. 5. Antiallodynic effect of Eta (10 mg/kg, p.o.) single treatment in neuropathic
mice (A). The mechanical allodynia was observed 0.5, 1, 2, or 4 h after Eta (10
mg/kg, p.o.) or vehicle (10 mg/mL, p.o.) administration in mice 7 days after the
induction of neuropathic nociception (A, partial nerve ligation procedure) or sham
procedure (B). Basal values (B) were observed before the procedure. Data are
expressed as the mean7S.E.M. of the mechanical painful hypersensitivity,
expressed as 50% mechanical paw withdrawal threshold (PWT) in g of 7 animals.
**po0.01, ***po0.001, compared with time 0 values (7 days after the procedure),
or #po0.001, compared with basal values (B) (two-way ANOVA followed by
Bonferroni post-hoc test).
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treatment of Eta on AChE activity. We observed that the incubation of
Eta (1 and 10 mg/mL) in vitro did not alter AChE activity in blood or
spinal cord samples (Table 1). However, we observed an increase in
the ex vivo AChE activity in lumbar spinal cord, but not in blood, of
animals treated with CFA when compared with intraplantar saline
injected mice (Fig. 7A and B). We also observed that Eta treatment
prevented the increase in AChE activity produced by the CFA
injection in lumbar spinal cord, however, it did not alter the enzyme
activity in saline injected mice (Fig. 7A).3.6. Toxicological evaluation
To investigate if repeated treatment with Eta induces toxicity,
we collected blood samples for ALT, AST and urea measurement;
and spleen, heart, liver, kidney and stomach of the animals
injected with CFA or saline intraplantarly and repeated treated
with Eta or vehicle. After the seven days of treatment, animals did
not present any alteration in overall behavior as well as blood
parameters analyzed or organ weight (Fig. 8 and Table 2). The
serum levels of the hepatic injury indicators (activity of AST and
ALT, UI/mL) and renal injury indicator (content of urea, mg/dL)
were not modiﬁed by repeated treatment with the Eta when
compared with vehicle-treated animals (Fig. 8). However, we
observed an increase in the level of the ALT activity of animals
injected with CFA when compared with vehicle-treated animals(Fig. 8A). These results may indicate that the repeated treatment
presents good safety and efﬁcacy.4. Discussion
The infusion or decoction of Mirabilis jalapa leaves is used in
traditional medicine in Brazil to treat inﬂammatory and painful
diseases. In the present study, we demonstrated that Eta produces
antinociception in animal models of arthritic, postoperative and
neuropathic pain. Moreover, the cholinergic system seems to be
involved in the antinociceptive action of Eta.
Chronic inﬂammation state represents one of the most pre-
valent chronic health problems that cause functional disability,
signiﬁcant pain and joint destruction, leading to premature
mortality (Kvien, 2004). Conventional medicine, including treat-
ment with steroids, non-steroidal anti-inﬂammatory drugs as well
as tumor necrosis factor-α (TNFα) and interleukin-1 β (IL-1β)
antagonists, has shown only limited success against all forms of
chronic inﬂammation, as arthritis. Along with these therapies, folk
medicine has been an alternative to treat arthritis and other
inﬂammatory process several plants have shown effective results
in the treatment of painful diseases, such as arthritis (Zhanga et al.,
2009). In this study we used the model of intraplantar injection of
CFA as a model of chronic inﬂammation, since it is effective in
mimicking some characteristics of human arthritis, such as the
development of mechanical allodynia, edema and induction of
Fig. 6. Prevention of Eta antiallodynic effect on CFA-induced inﬂammatory noci-
ception by atropine (A) or mecamelamyne (B). Atropine (5 mg/kg, s.c.) or meca-
mylamine (0.001 mg/kg, s.c.) were administered 15 min before Eta (10 mg/kg, p.o.)
or vehicle (10 mL/kg, p.o.) injection. The mechanical allodynia was observed 1 h
after Eta or vehicle administration in mice. Basal values (B) were observed before
the CFA paw injection. Data are expressed as the mean7S.E.M. of mechanical
painful hypersensitivity, expressed as mechanical paw withdrawal threshold (PWT)
in g of 5–7 animals. ***po0.001, compared with before CFA treatment values (48 h
after CFA injection); #po0.001, compared with basal values (B); or dpo0.01,
compared with animals treated with vehicle plus Eta (two-way ANOVA followed by
Bonferroni post-hoc test).
Table 1
Acetylcholinesterase activity in blood and lumbar spinal cord samples in the
presence or absence of Eta (1 or 10 mg/mL) (n¼45). Results are expressed as
Δextinction/minute.
Treatment Blood Spinal cord
Vehicle 11.03270.002 44.00570.002
Eta (1 lg/mL) 13.00670.001 53.01070.003
Eta (10 lg/mL) 12.04070.002 51.00470.003
Fig. 7. Effect of Eta (10 mg/kg, p.o.) or vehicle (10 mg/mL, p.o.) single treatment on
acetylcholinesterase activity in samples of lumbar spinal cord (A) or blood (B) of
saline or CFA-pretreated animals. The acetylcholinesterase activity was observed
1 h after Eta (10 mg/kg, p.o.) or vehicle (10 mg/mL, p.o.) administration in mice
pretreated (48 h prior) intraplantarly with CFA or saline. Data are expressed as the
mean7S.E.M. of mM of ATC hydrolyzed/h/mg of protein of 3–5 animals. #po0.05
denotes the signiﬁcance level when compared with saline plus vehicle-treated
animals; ***po0.001 denotes the signiﬁcance level when compared with vehicle
plus CFA-treated mice (one-way ANOVA followed by Bonferroni post hoc test).
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the current study, we demonstrated that a single oral administra-
tion of Eta produced antinociceptive, but not anti-edematogenic
action, in CFA-induced painful inﬂammation in mice. On the other
hand, the repeated treatment with Eta was capable of reducing
both nociception and edema produced by CFA, without altering
the levels of the pro-inﬂammatory cytokine IL-1β in the inﬂamed
tissue. Since the treatments started 2 days after CFA injection, both
single and repeated treatments with Eta were effective in rever-
sing an established painful hypersensitivity, which is similar to the
curative effect produced by the drugs clinically used to treat
arthritis (Attal et al., 1988; Ferreira et al., 2001; Rossato et al.,2011). Furthermore, Eta had a cumulative effect after the second
day of treatment because its effects began to appear 24 h after the
second administration. Taken together, these ﬁndings are certainly
relevant, considering that chronic pain is difﬁcult to treat since it is
quite resistant to most of the analgesic drugs currently available
on the market (Ashburn and Staats, 1999).
Non-steroidal or steroidal anti-inﬂammatory drugs have been
reported to reduce the development of allodynia and paw swelling
in inﬂammation induced by injection of adjuvant-induced inﬂam-
mation in rodents, while opiates produce antiallodynic, but not
anti-edematogenic effects (Li and Zhao, 2003; Nagakura et al.,
2003). Moreover, steroidal, but not non-steroidal anti-inﬂamma-
tory drugs reduced the levels of pro-inﬂammatory cytokines in
CFA-injected tissue (Saﬁeh-Garabedian et al., 1995). Thus, the
proﬁle of the effect exerted by Eta in CFA-induced inﬂammation
is similar to non-steroidal anti-inﬂammatory drugs and different
from opiates. Accordingly, we detected that the antiallodynic
effects of Eta were not susceptible to tolerance (as occurs
with opioids), once the effect remains unaltered during the
treatment and the antinociception produced by Eta administration
in an acute pain model was not reversed by naloxone (Walker
et al., 2008).
In several painful processes, the participation of cholinergic
system is well known. Some studies described the anti-
inﬂammatory and anti-nociceptive effect of cholinergic activation
(Schechtmann et al., 2008; Rosas-Ballina and Tracey, 2009).
Recently, we reported that the treatment with muscarinic antago-
nist completely prevented the antinociceptive effect of Eta in an
acute model of pain (Walker et al., 2008). Here, we investigated
whether or not cholinergic receptors could be involved in
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Fig. 8. The repeated treatment with Eta on the parameters of hepatic (A and B)
or renal (C) injury in mice serum. The activity of alanine aminotransferase
(A, ALT) or aspartate aminotransferase (B, AST), and the content of urea (C) were
assessed in animals serum treated for 7 days with Eta (10 mg/kg, p.o.) or
vehicle (10 mg/mL, p.o.), and also submitted to chronic inﬂammation induced by
CFA intraplantar injection or control animals (saline injection). *po0.05
denotes the signiﬁcance level when compared with vehicle-treated mice (1-way
ANOVA followed by SNK test), #po0.05 compared with vehicle group, one-way
ANOVA followed by SNK test. The results represent the mean7S.E.M. of 3–5
animals.
Table 2
Toxicological parameters evaluated in tissue and blood samples after chronicle
treatment with vehicle (10 mg/mL, p.o.) or Eta (10 mg/kg, p.o.) during 7 days (n¼
4–5). Results are expressed as mean7S.E.M. for 4–5 per group.
Treatment % Body weight
Spleen Stomach Heart Kidney Liver
Sal—Vehicle 0.4370.05 1.270.16 0.5770.03 4.8370.39 5.2770.39
Sal—Eta 0.4470.05 1.1770.14 0.4870.04 4.7570.36 5.3270.14
CFA—Vehicle 0.4370.02 1.0570.16 0.4970.03 4.6670.13 5.5770.12
CFA—Eta 0.3870.02 1.0970.06 0.6370.05 4.7270.33 5.5770.12
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to that observed in the acute model, muscarinic receptors are
involved in the antinociceptive action induced by Eta in CFA-
induced painful inﬂammation. Extending our previous ﬁndings,
we have shown here that the nicotinic receptor stimulation is also
responsible for the antinociceptive action of Eta. As the antago-
nists of nicotinic and muscarinic receptors produced a complete
prevention of the Eta-induced antinociception, we suggest a
sequential mechanism of receptor activation, as previously
described (Zarrindast and Farzin, 1996).
Once the inhibition of AChE, the enzyme that degraded ACh,
could increase the levels of ACh and ACh activates the muscarinic
and nicotinic receptor (Yoon et al., 2003), we investigated its
activity in the Eta-induced effects in CFA model. We observed an
increase in the ex vivo AChE activity in the spinal cord, but not in
blood, of animals injected with CFA. Thus, the decrease in the
cholinergic tonus at the spinal cord may be associated with the
sensitization process that occurs at the spinal cord in chronic
painful processes. In fact, our ﬁndings are in accordance with
studies showing that the major site of action for cholinomimetics
in analgesia is the spinal cord (Jones and Dunlop, 2007) and that
painful stimuli are known to increase acetylcholine levels in the
spinal cord (Eisenach et al., 1997).
We have also found that the repeated treatment with Eta was
able to completely prevent the increase in the AChE activity in
CFA-injected animals; however, the in vitro incubation of Eta did
not alter the AChE activity. This result suggests that the reduction
of the AChE activity promoted by Eta ex vivo is not due to a direct
mechanism, since the incubation of Eta in vitro did not alter the
AChE activity. Of note, AChE is anchored to the plasma membrane
and there lipid peroxidation seems to induce the AChE activation
(Kaizer et al., 2005). Moreover, we previously demonstrated that
CFA-related nociception is mediated by an increase of oxidative
stress in the spinal cord of mice (Rossato et al., 2011) and that Eta
possesses antioxidant activity (Walker et al., 2009). Thus, Eta
exerting its antioxidant effect could prevent lipid peroxidation
and, indirectly, reverse the increase in AChE activity, which could
explain its antinociceptive action. However, more studies must be
carried out to elucidate this point.
Another important chronic painful condition is the neuropathy.
Neuropathic pain is one of the most difﬁcult conditions to treat in
clinical practice (Ibrahim et al., 2003). The analgesic drugs avail-
able often have limited therapeutic value in the management of
neuropathic pain and they may, in fact represent a risk to the
patient because of their common side effects (Joe and Wilder,
1999). For this reason, it is extremely important to develop drugs
to safely and effectively treat chronic pain. In our experiments, oral
administration of Eta, markedly produced a decrease in the
mechanical allodynia induced by partial nerve ligation, a model
of neuropathic pain (Kassuya et al., 2003). Thus, the Eta seems to
exert antinociceptive effect in pathological pain of different
etiologies.
Besides chronic pain, some forms of acute pain remain a
problem in many patients, such as postoperative pain. The treat-
ment with high doses of opiates required to control postoperative
pain is often associated with adverse side effects (Brennan et al.,
1997; Benowitz, 2008). Thus, we examined the possible preventive
and curative effect and antiallodynic effect of Eta in a model of
postoperative pain that displays similarities to the human post-
operative pain syndrome, where surgical incision causes mechan-
ical allodynia (Brennan et al., 1997; Pogatzki and Raja, 2003). In
our experiments, oral administration of the Eta, both in pre- and
postoperative periods markedly decreased in mechanical allodynia
induced by skin paw incision. Eta was more effective to prevent
than to reverse the installed pain. This result is not unexpected
since the treatment of pain before surgery prevents the plastic
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cation of pain long after the initial stimulus (Brennan et al., 1997).
The serum activity of AST and ALT, or the urea content were
analyzed in order to identify possible hepatic and renal lesions
after repeated treatment with Eta. The Eta treatment did not
produced any alteration in these parameters, suggesting that Eta is
not toxic in mice, in the conditions where they had been tested.
In conclusion, the present ﬁndings indicate that the Eta
produces antinociceptive in clinically relevant models of pain
without the induction of tolerance, namely chronic inﬂammation,
postoperative and neuropathic pain model. Also this effect in the
chronic inﬂammation model seems to be mediated by the activa-
tion of cholinergic system, through AchE inhibition. Thus, the
present ﬁndings conﬁrm the ethnopharmacological indication of
Mirabilis jalapa preparations to treat different painful diseases.Acknowledgments
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